Glucocorticoids have the potential to reduce mortality for patients with severe community-acquired pneumonia (CAP), but the effects could vary based on type and dosing, according to results of a study published in European Journal of Medical Research. However, there has been controversy surrounding the clinical use in practice of these drugs due to the safety profile.1,2
Glucocorticoid use for severe community-acquired pneumonia has been controversial due to the safety profile of these drugs. | Image Credit: Andrii – stock.adobe.com
In a previous study published in the European Respiratory Review, the study authors state that glucocorticoids “exhibit potent anti-inflammatory and immunomodulatory properties, potentially mitigating the impact of pneumonia.” The overall effect of these drugs remains unknown, and…